JP Morgan Chase
ZBIO

JP Morgan Chase’s Zenas BioPharma ZBIO Stock Holding History

JP Morgan Chase’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$661K Sell
24,445
-664
-3% -$13.2K ﹤0.01% 4930
2026
Q1 		$458K Buy
25,109
+3,383
+16% +$75.9K ﹤0.01% 5087
2025
Q4 		$789K Buy
21,726
+15,178
+232% +$499K ﹤0.01% 4754
2025
Q3 		$145K Sell
6,548
-1,128
-15% -$18.4K ﹤0.01% 5702
2025
Q2 		$74.4K Buy
7,676
+409
+6% +$3.98K ﹤0.01% 5742
2025
Q1 		$57.4K Sell
7,267
-22,572
-76% -$177K ﹤0.01% 5829
2024
Q4 		$244K Buy
+29,839
New +$465K ﹤0.01% 5389

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

JP Morgan Chase's ZBIO Position: Q2 2026 in Review

JP Morgan Chase reduced its Zenas BioPharma (ZBIO) stake by 2.6% in Q2 2026, selling an estimated $13.2K and leaving 24,445 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #4930.

JP Morgan Chase first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $789K in Q4 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • JP Morgan Chase held 24,445 shares of Zenas BioPharma worth $661K as of Q2 2026.
  • JP Morgan Chase sold 664 Zenas BioPharma shares in Q2 2026, an estimated $13.2K.
  • Zenas BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4930 holding.
  • JP Morgan Chase first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Zenas BioPharma position peaked at $789K in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.